Compugen closed at $2.12 on Nov 12, up 1.44%, 31.6% below its 52-week closing high. Volume of 190.2K shares was 0.78× its 20-day average (below normal).
Split-adjusted performance: +6.0% over one month, -30.0% over six months, +23.3% over one year.
Short interest was 2.5M shares at the Oct 30 settlement (2.7% of float, 9.7 days to cover).
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally.
What is CGEN's market cap?
$200.82M, based on the Nov 12 close of $2.12.
Does Compugen pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CGEN is sold short?
2.5M shares, 2.7% of float, as of Oct 30, 2026.
About Compugen
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
